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INTRODUCTION
Allergic rhinitis (AR) is an inflammatory disease of the nasal 
mucosa caused by an allergen-IgE interaction in sensitized in-
dividuals; it is characterized by the clinical symptoms of sneez-
ing, itching, congestion, rhinorrhea, and nasal blockage.
1,2 Asth-
ma is characterized by chronic inflammation of the lower air-
ways and shares several characteristics with AR.
3,4 In both con-
ditions, an inflammatory response is triggered by similar factors 
such as allergens, leading to the increased production and re-
lease of inflammatory mediators, including interleukin (IL)-4, 
IL-5, IL-13, granulocyte-macrophage colony-stimulating factor, 
histamine, leukotrienes, prostaglandins, eotaxin, and thymus 
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and activation-regulated chemokine, as well as the upregulation 
of adhesion molecules common to both asthma and AR. As a 
result, inflammatory cells such as eosinophils, T-cells, basophils, 
and mast cells begin to infiltrate both the nasal mucosa and the 
lungs.
5,6 The recruitment and migration of inflammatory cells 
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Purpose:  Allergic rhinitis (AR) and asthma share many characteristics, but structural changes are observed far less often in AR. Matrix metallopro-
teinases (MMPs) constitute a family of Zn-dependent endopeptidases that can decompose the extracellular matrix and basement membrane, and 
regulate cell infiltration. We analyzed the expression of MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), in allergic nasal 
mucosa after nasal allergen challenge (NAC) and determined their relationship to inflammatory cells.  Methods:  Nasal mucosa specimens were 
obtained at surgery performed for hypertrophied turbinates. We performed NAC with house dust mite (HDM) allergen disks and control disks, and 
took biopsies at 30 minutes, 6 hours, and 12 hours after NAC. Cells expressing MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2, as well as eosino-
phils and mast cells, were analyzed immunohistochemically. The MMPs and TIMPs in allergic nasal mucosa were quantified using enzyme-linked 
immunosorbent assays.  Results:  At 30 minutes post-NAC, HDM-exposed nasal mucosa exhibited significantly more MMP-2+, MMP-9+, MMP-
13+, TIMP-1+, and TIMP-2+ cells compared with control mucosa, and the numbers of MMP-9+ and TIMP-1+ cells correlated strongly with the num-
ber of mast cells. At 6 hours post-NAC, the numbers of MMP+ and TIMP+ cells did not differ significantly between HDM-exposed mucosa and con-
trol mucosa, but the ratios of MMP+ cells to TIMP+ cells were higher in HDM-exposed mucosa. At 12 hours post-NAC, the number of MMP-13+ 
cells tended to be higher in HDM-exposed mucosa and was strongly correlated with the number of eosinophils. Quantitatively, the levels of MMP-2 
and MMP-13 were significantly higher than the MMP-9 level, and the TIMP-2 level was significantly higher than the TIMP-1 level in allergic nasal 
mucosa.  Conclusions:  We demonstrated increased expression of MMP-2, MMP-9, and MMP-13 in allergic nasal mucosa, high MMPs-to-TIMP-1 
ratios, and a strong correlation between MMP-9 and mast cells and between MMP-13 and eosinophils. The imbalance between MMPs and TIMPs 
may contribute to the migration of inflammatory cells such as eosinophils and mast cells to the nasal mucosa of AR patients, suggesting a possible 
active role of MMPs in AR.
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involve traversing capillary vessel walls and the interstitium, and 
require degradation of extracellular matrix (ECM) proteins by 
secreted matrix metalloproteinases (MMPs),
7 although the pre-
cise underlying mechanism is not fully understood.
The basement membrane is composed of various substances 
such as cell adhesive molecules and ECM-like type IV collagen, 
type VII collagen, laminin, fibronectin, and heparin sulfate.
8 
MMPs comprise a family of Zn-dependent endopeptidases that 
can decompose the ECM and basement membrane.
9 They par-
ticipate in tissue remodeling, cell infiltration, and tumor spread. 
At least 23 MMP family members have been characterized.
10,11 
In particular, MMP-2 and MMP-9 degrade type IV and V colla-
gens as well as elastin and thus may facilitate cell migration. In 
addition, MMP-2, MMP-9, and MMP-13 are thought to play key 
roles in tissue remodeling and repair through degradation of 
type IV collagen, which is the major component of the base-
ment membrane.
12
The activation of MMPs is inhibited by tissue inhibitors of me-
talloproteinases (TIMPs), which form a 1:1 complex with 
MMPs.
9,10 Four different TIMPs have been identified. TIMP-1 
binds to both the active and precursor forms of MMP-9, where-
as TIMP-2 and TIMP-4 bind to pro-MMP-2, MMP-2, and MMP-
9, which are linked to gelatinolytic activity and chronic obstruc-
tive pulmonary disease.
9 Another study suggested that MMP-2 
and MMP-9 are inactivated by TIMP-1 and TIMP-2.
13 Loss of 
the coordinated expression of MMPs and TIMPs is believed to 
generate tissue degradation under inflammatory conditions.
Epithelial cells and fibroblasts express and release MMPs.
14 
Additionally, eosinophils are a major source of MMPs; MMP-9 
was shown to be overexpressed by eosinophils accumulating in 
airway walls of asthmatics.
15 Several in vitro studies have dem-
onstrated that MMP-2 and MMP-9 are produced and activated 
by mast cells, and the possible involvement of mast cells in con-
nective tissue degradation and fibrosis was suggested.
16,17
In asthma, inflammation and repair of the airways are ongo-
ing processes, involving epithelial shedding and thickening of 
the basement membrane.
18,19 In a study that evaluated bronchi-
al biopsies, increased levels of fibronectin and type I and type 
III collagen were detected in the basement membrane of asth-
matic subjects compared with subjects with seasonal allergic 
rhinitis and healthy controls.
20 However, epithelial shedding, 
basement membrane thickening, and fibrosis are observed far 
less often in AR.
12,21 These differences may reflect structural dif-
ferences and remodeling alterations in asthma versus AR. By 
contrast, nasal polyps share more features with asthma. As in 
asthma, nasal polyps exhibit increased MMP-9 expression and 
low TIMP levels.
22
We hypothesized that MMPs may play a role in regulating cell 
infiltration in allergic nasal mucosa. To investigate this, we ana-
lyzed the expression of MMPs and TIMPs in allergic nasal mu-
cosa after nasal allergen challenge (NAC) and determined their 
relationship to inflammatory cells.
MATERIALS AND METHODS
Patient profile
Thirty patients (mean age, 26 years; range, 10-65 years) with 
perennial allergic rhinitis (PAR) to house dust mite (HDM) al-
lergen were included in the present study. Of the 30 patients, 24 
were males and 6 were females (male:female=4:1). Ten pa-
tients had co-morbid asthma, three had chronic rhinosinusitis, 
and three had atopic dermatitis. AR was diagnosed based on a 
typical symptom history of sneezing, rhinorrhea, and nasal 
congestion; clinical examination by anterior rhinoscopy; posi-
tive serum-specific IgE on a radioallergosorbent test (RAST); 
and positive allergy skin test results. Nineteen of the 30 subjects 
had seasonal AR to Japanese cedar pollen; eight, to timothy 
grass pollen; and seven, to ragweed pollen. All patients were 
symptomatic at the time nasal mucosal tissue samples were 
collected at surgery performed as partial treatment for hyper-
trophied turbinates. Another six patients (4 males and 2 fe-
males) with PAR to HDM allergen were included for the en-
zyme-linked immunosorbent assay (ELISA) study. Medications 
were prohibited for at least 1 month prior to surgery. The study 
was approved by the Nippon Medical School Medical Ethics 
Committee, and informed consent was obtained from all pa-
tients.
Nasal challenge and collection and processing of specimens
Nasal mucosal specimens from subjects who had severe nasal 
obstruction and hypertrophied turbinates due to AR were ob-
tained at surgery (conchotomy) performed for the treatment of 
hypertrophied turbinates. The NAC was conducted by placing a 
HDM allergen disk on the anterior end of the inferior turbinate 
of one side and a control disk on the contralateral side at 30 
minutes (n=10), 6 hours (n=10), or 12 hours (n=10) before the 
specimens were collected at surgery. These time points reflect 
the early-phase and late-phase allergic reaction. Nasal mucosa 
specimens were rinsed in phosphate-buffered saline (PBS, pH 
7.6) and processed for immunohistochemistry as described be-
low.
Processing of specimens for immunohistochemistry
Nasal mucosa tissue specimens were fixed in periodate-lysine-
paraformaldehyde (PLP) and then incubated for 4 hours each 
in 10%, 15%, and 20% sucrose in PBS. The specimens were em-
bedded in Tissue-Tek OCT compound (Miles Laboratories, Inc., 
Elkhart, IN, USA), frozen in liquid nitrogen, and stored at -80°C 
until further use.
Immunohistochemical analysis of MMP-2, MMP-9, MMP-13, 
TIMP-1, and TIMP-2 expression
Immunohistochemistry was performed to analyze the expres-
sion of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 in nasal 
mucosa challenged with allergen or control disks. Frozen sec-MMPs and TIMPs in Allergic Rhinitis
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tions of PLP-fixed specimens were cut at 4 μm thickness using a 
cryostat (Sakura Finetek, Tokyo, Japan), mounted on silane-
coated slides, air-dried for 30 minutes, and then fixed in 100% 
acetone for 10 minutes. Immunohistochemistry for the detec-
tion of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 was 
performed using the alkaline phosphatase/anti-alkaline phos-
phatase (APAAP) method with an APAAP kit (Nichirei Biosci-
ence, Tokyo, Japan). Briefly, acetone-fixed sections were rehy-
drated by incubation in Tris-buffered saline (TBS, pH 7.4), fol-
lowed by incubation in 10% H2O2 for 30 minutes to block en-
dogenous peroxidase activity. After two rinses in TBS, the sec-
tions were incubated in Protein Block Serum (Dako Japan, To-
kyo, Japan). After two more rinses in TBS, the sections were in-
cubated for 12 hours at 4°C with a primary antibody: mouse an-
ti-human MMP-2, mouse anti-human MMP-9, mouse anti-hu-
man MMP-13, mouse anti-human TIMP-1, or mouse anti-hu-
man TIMP-2 antibody (Daiichi Fine Chemical, Toyama, Japan) 
at the optimal concentration (10 μg/mL). Then, the sections 
were rinsed twice in TBS, incubated in rabbit anti-mouse im-
munoglobulin (Nichirei Bioscience, Tokyo, Japan) for 30 min-
utes at room temperature, rinsed twice in TBS, and incubated 
in APAAP regent (Nichirei Bioscience) for 30 minutes at room 
temperature, followed by incubation with 3-amino-9-ethylcar-
baxol (AEC) substrate (Dako Japan). After being rinsed twice in 
distilled water (DW), the sections were incubated for 30 sec-
onds in Mayer’s hematoxylin, rinsed twice in DW, and mount-
ed in Dako gel (Dako). For the negative control, the primary an-
tibodies were substituted with an irrelevant isotype-matched 
mouse IgG (IgG1; Dako).
Immunohistochemical detection of tryptase-positive cells 
(mast cells) and major basic protein (MBP) expression 
(eosinophils)
Immunohistochemistry to detect tryptase expression (mast 
cells) was performed using the same method as described above, 
using mouse anti-human mast cell tryptase (Chemicon Inter-
national, Temecula, CA, USA) at the optimal concentration (10 
μg/mL) as the primary antibody. For the negative control, the 
primary antibody was substituted with an irrelevant isotype-
matched mouse IgG (IgG1; Dako).
To investigate the expression and localization of MBP in nasal 
mucosa, immunohistochemistry was performed using the per-
oxidase-based avidin-biotin complex (ABC) method (ABC kit; 
Vector Laboratories, Burlingame, CA, USA). Briefly, the speci-
mens were incubated in 10% H2O2 for 30 minutes to block en-
dogenous peroxidase activity, rinsed twice in TBS, and incubat-
ed in Protein Block Serum (Dako). After two rinses in TBS, the 
sections were incubated with the primary antibody, mouse an-
ti-human MBP (BD Biosciences, CA, USA), at an optimal con-
centration (5 μg/mL) for 12 hours at 4°C. The sections were 
rinsed twice in TBS and incubated with biotin-labeled horse 
anti-mouse immunoglobulin (Dako) for 30 minutes at room 
temperature. After two rinses in TBS, the sections were incubat-
ed in ABC reagent (Dako) for 30 minutes at room temperature, 
followed by incubation with the ABC substrate. Finally, the sec-
tions were rinsed twice in DW, counterstained with Mayer’s he-
matoxylin, and mounted in Dako gel (Dako). For the negative 
control, the primary antibody was substituted with an irrelevant 
isotype-matched mouse IgG (IgG1; Dako).
Cell counting
The number of cells staining positive for MMP-2, MMP-9, 
MMP-13, TIMP-1, TIMP-2, tryptase, or MBP in each of 10 ran-
domly selected visual fields (0.202 mm
2 each) of each section 
was counted under an Olympus microscope (Olympus, Tokyo, 
Japan) at ×400 high power field (HPF) magnification using an 
objective micrometer. The number of positively stained cells in 
a section is expressed as the mean±standard error (SE) of the 
10 cell counts for that section.
ELISA for MMPs and TIMPs
Unchallenged nasal mucosa tissues from six additional pa-
tients with PAR to HDM allergen were homogenized using ul-
trasonification. The samples were clarified by high-speed cen-
trifugation, and the supernatants were collected and stored at 
-20°C until further use. The levels of MMP-2, MMP-9, MMP-13, 
TIMP-1, and TIMP-2 in nasal mucosa extracts were measured 
using specific ELISA kits according to the manufacturer’s in-
structions (Amersham Biosciences, Piscataway, NJ, USA). Each 
sample was analyzed in duplicate. The total protein in the nasal 
mucosa was analyzed using a BCA protein assay kit (Pierce Bio-
technology, Inc., Rockford, IL, USA). The levels of MMPs and 
TIMPs are expressed as ng/mg protein.
Statistical analysis
Statistical significance for intergroup comparisons was deter-
mined by the Wilcoxon signed-rank test. Correlation was deter-
mined using Spearman’s coefficient test. Differences were 
deemed to be significant for values of P<0.05. All statistical 
analyses were performed using statistical program software 
(OMS, Saitama, Japan).
RESULTS
Expression of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 
in allergic nasal mucosa
MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 were all ex-
pressed in the nasal mucosa of PAR patients (Fig. 1). Morpho-
logically, all five proteins were observed mainly in inflammato-
ry cells. In addition, MMP-2 was also present in epithelial cells, 
fibroblasts, and endothelial cells; MMP-9, in epithelial cells, fi-
broblasts, and acinar cells; MMP-13, in fibroblasts, endothelial 
cells, and acinar cells; and TIMP-1 and TIMP-2, in fibroblasts, 
epithelial cells, and endothelial cells. The negative control Mori et al.
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showed no immunoreactivity for MMP-2, MMP-9, MMP-13, 
TIMP-1, or TIMP-2.
Number of cells expressing MMPs and TIMPs at 30 minutes 
post-NAC
The numbers of cells staining positive for MMPs and TIMPs in 
the allergic nasal mucosa of PAR patients at 30 minutes post-
NAC are shown in Fig. 2A and 2B. Compared with the nasal 
mucosa exposed to the control disk, the nasal mucosa exposed 
to the HDM allergen disk at 30 minutes exhibited significantly 
more cells expressing MMP-2 (12.9±3.36 vs. 5.3±1.69, HDM 
vs. control; P<0.02), MMP-9 (9.8±2.52 vs. 5.1±1.41, HDM vs. 
control; P<0.05), MMP-13 (14.1±3.37 vs. 8.3±1.55, HDM vs. 
control; P<0.05), TIMP-1 (13.6±3.4 vs. 4.5±1.26, HDM vs. con-
trol; P<0.02), and TIMP-2 (15.2±3.68 vs. 5.0±1.24, HDM vs. 
control; P<0.02).
Number of cells expressing MMPs and TIMPs at 6 hours post-
NAC
The numbers of cells staining positive for MMPs and TIMPs in 
the allergic nasal mucosa of PAR patients at 6 hours post-NAC 
are shown in Fig. 3A and 3B. After 6 hours, there was no signifi-
cant difference between the HDM-exposed and control-exposed 
nasal mucosa with respect to the number of cells expressing 
MMP-2 (16.8±2.88 vs. 11.7±2.42, HDM vs. control), MMP-9 
(7.8±3.6 vs. 5.3±1.8, HDM vs. control), MMP-13 (12.9±3.43 
vs. 11.7±6.16, HDM vs. control), TIMP-1 (8.6±2.88 vs. 11.6±
2.99, HDM vs. control), or TIMP-2 (14.8±3.58 vs. 1.6±2.99, 
HDM vs. control).
Fig. 1.  Immunoreactivity and localization of MMP-2, MMP-9, MMP-13, TIMP-
1, and TIMP-2 in the nasal mucosa of PAR patients. Immunohistochemistry us-
ing the APAAP method was performed as described in the Materials and Meth-
ods section. (A) MMP-2 was expressed mainly in inflammatory cells, but also in 
fibroblasts, epithelial cells, and endothelial cells. (B) MMP-9 was expressed 
mainly in inflammatory cells, but also in fibroblasts, epithelial cells, and acinar 
cells. (C) MMP-13 was expressed mainly in inflammatory cells, but also in fibro-
blasts, endothelial cells, and acinar cells. (D) TIMP-1 was expressed mainly in 
inflammatory cells, but also in fibroblasts, epithelial cells, and endothelial cells. 
(E) TIMP-2 was expressed mainly in inflammatory cells, but also in fibroblasts 
and endothelial cells. (F) The negative control showed no immunoreactivity 
(magnification, ×200-400 HPF).
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Fig. 2. The numbers of MMP-2+, MMP-9+, MMP-13+, TIMP-1+, and TIMP-2+ cells in the nasal mucosa of PAR patients at 30 min after NAC with HDM allergen 
disks versus control disks. Immunohistochemistry using the APAAP method was performed as described in the Materials and Methods section. Positively stained 
cells in an area of 0.202 mm
2 were counted at ×400 HPF. Box plots represent the median values with 25 and 75% interquartiles. Error bars represent the 10th and 
90th percentiles; the squares indicate the means. (A) At 30 min post-NAC, the numbers of MMP-2+, MMP-9+, and MMP-13+ cells in the HDM-exposed mucosa 
were significantly higher than those in the control-exposed mucosa (n=10). (B) At 30 min post-NAC, the numbers of TIMP-1+ and TIMP-2+ cells in the HDM-exposed 
mucosa were significantly higher than those in the control-exposed mucosa (n=10). *P<0.05, **P<0.02, by Wilcoxon signed-rank test.
N
u
m
b
e
r
 
o
f
 
c
e
l
l
s
/
H
P
F
50
45
40
35
30
25
20
15
10
5
0
Control
disk
TIMP1
Allergen
disk
**
TIMP2
Control
disk
Allergen
disk
**
N
u
m
b
e
r
 
o
f
 
c
e
l
l
s
/
H
P
F
50
45
40
35
30
25
20
15
10
5
0
Control
disk
MMP2
Allergen
disk
**
MMP9
Control
disk
Allergen
disk
*
MMP13
Control
disk
Allergen
disk
*
A BMMPs and TIMPs in Allergic Rhinitis
Allergy Asthma Immunol Res. 2012 July;4(4):231-239.  http://dx.doi.org/10.4168/aair.2012.4.4.231
AAIR 
235 http://e-aair.org
Number of cells expressing MMPs and TIMPs at 12 hours post-
NAC
The numbers of cells staining positive for MMPs and TIMPs in 
the allergic nasal mucosa of PAR patients at 12 hours post-NAC 
are shown in Fig. 4A and 4B. Although the numbers of cells ex-
pressing each of the MMPs and TIMPs at 12 hours were greater 
in the HDM-exposed nasal mucosa compared with the control-
exposed nasal mucosa, the difference was not significant for 
MMP-2 (9.6±3.94 vs. 4.8±1.02, HDM vs. control), MMP-9 
(8.9±3.56 vs. 3.7±1.16, HDM vs. control), MMP-13 (11.1±3.48 
vs. 5.5±1.47, HDM vs. control), TIMP-1 (8.7±3.26 vs. 6.6±1.41, 
HDM vs. control), or TIMP-2 (9.8±2.68 vs. 8.8±1.98, HDM vs. 
control).
Ratio of MMP+ to TIMP+ cells
We analyzed the ratios of cells expressing MMPs to cells ex-
pressing TIMPs in the nasal mucosa of PAR patients. The MMP-
2/TIMP-1, MMP-9/TIMP-1, and MMP-13/TIMP-1 ratios in the 
Fig. 3. The numbers of MMP-2+, MMP-9+, MMP-13+, TIMP-1+, and TIMP-2+ cells in the nasal mucosa of PAR patients at 6 hr after NAC with HDM allergen disks 
versus control disks. Immunohistochemistry using the APAAP method was performed as described in the Materials and Methods section. Positively stained cells in 
an area of 0.202 mm
2 were counted at ×400 HPF. Box plots represent the median values with 25 and 75% interquartiles. Error bars represent the 10th and 90th per-
centiles; the squares indicate the means. (A) At 6 hr post-NAC, there was no significant difference in the number of MMP-2+, MMP-9+, or MMP-13+ cells between 
HDM-exposed and control-exposed nasal mucosa (n=10). (B) At 6 hr post-NAC, there was no significant difference in the number of TIMP-1+ or TIMP-2+ cells be-
tween HDM-exposed and control-exposed nasal mucosa (n=10).
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Fig. 4. The numbers of MMP-2+, MMP-9+, MMP-13+, TIMP-1+, and TIMP-2+ cells in the nasal mucosa of PAR patients at 12 hr after NAC with HDM allergen disks 
versus control disks. Immunohistochemistry using the APAAP method was performed as described in the Materials and Methods section. Positively stained cells in 
an area of 0.202 mm
2 were counted at ×400 HPF. Box plots represent the median values with 25 and 75% interquartiles. Error bars represent the 10th and 90th per-
centiles; the squares indicate the means. (A) At 12 hr post-NAC, there was no difference in the number of MMP-2+, MMP-9+, or MMP-13+ cells between HDM-ex-
posed and control-exposed nasal mucosa (n=10). (B) At 12 hr post-NAC, there was no difference in the number of TIMP-1+ or TIMP-2+ cells between HDM-exposed 
and control-exposed nasal mucosa (n=10).
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HDM-exposed mucosa were higher than the respective ratios 
in the control-exposed mucosa at 6 hours after NAC, but the ra-
tios did not differ significantly (Table). However, the MMP-2/
TIMP-1 and MMP-13/TIMP-1 ratios showed a tendency of dif-
ference (P=0.07).
Correlation of MMPs and TIMPs with mast cells
Mast cells are increased specifically in the nasal epithelium of 
patients with allergic rhinitis. To understand the relationship 
between MMPs and the migration of mast cells to the nasal 
mucosa, particularly intraepithelial migration of mast cells, we 
analyzed the correlation between the number of cells express-
ing MMPs and the number of cells expressing tryptase, a mark-
er for mast cells. At 30 minutes after NAC, the number of mast 
cells was strongly correlated with the number of MMP-9+ cells 
(P<0.05, r=0.77) and the number of TIMP-1+ cells (P<0.05, r=
0.78) (Fig. 5).
Correlation of MMPs and TIMPs with eosinophils
To examine the relationship between MMPs and the migration 
of eosinophils into allergic nasal mucosa, we analyzed the cor-
relation between the number of cells expressing MMPs and the 
number expressing MBP, a marker for eosinophils. At 12 hours 
post-NAC, the number of eosinophils and the number of MMP-
13+ cells were strongly correlated (P<0.05, r=0.75) (Fig. 6).
Quantification of MMPs and TIMPs in allergic nasal mucosa
The amounts of MMPs and TIMPs in the nasal mucosa of pa-
tients with PAR were determined by ELISA (Fig. 7). The levels of 
MMP-2 (60.6±18.2 ng/mL) and MMP-13 (81.2±20.2 ng/mL) 
were higher than the level of MMP-9 (34.6±6.8 ng/mL) (P<0.05 
and P<0.02, respectively). The level of TIMP-2 (24.8±10.2 ng/
mL) was higher than the level of TIMP-1 (5.6±1.2 ng/mL) (P<
0.02).
DISCUSSION
MMPs represent a family of Zn-dependent endopeptidases 
capable of degrading essentially all components of the ECM.
9 
As the gelatinase subgroup of MMPs, MMP-2 and MMP-9 are 
Fig. 5. Correlation of MMP-9+ and TIMP-1+ cells with mast cells in the nasal mucosa of PAR patients. (A) There was a strong correlation between the number of 
mast cells and the number of MMP-9+ cells at 30 min after NAC with HDM allergen disks. (r=0.8, P<0.02, by Spearman’s rank correlation coefficient; n=10.) (B) 
There was a strong correlation between the number of mast cells and the number of TIMP-1+ cells at 30 min after NAC with HDM allergen disks. (r=0.8, P<0.05, 
by Spearman’s rank correlation coefficient; n=10.)
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Table. Ratio of the numbers of cells expressing a MMP vs. TIMP in the nasal mucosa of PAR patients
30 min 60 hr 12 hr
Control HDM Control HDM Control HDM
MMP2/TIMP1 1.17±0.43 1.09±0.14 2.78±1.39 5.87±3.40* 0.87±0.23 1.26±0.47
MMP9/TIMP1 1.13±0.27 0.92±0.25 0.80±0.24 2.20±1.35 0.58±1.13 1.28±0.40
MMP13/TIMP1 2.85±0.86 1.59±0.37 2.31±1.25 4.76±3.09* 0.83±0.26 1.40±0.62
MMP2/TIMP2 0.89±0.26 1.00±0.24 1.00±0.21 1.77±0.78 0.97±0.26 1.03±0.28
MMP9/TIMP2 0.91±0.15 0.84±0.17 1.29±0.77 0.72±0.34 0.61±0.15 0.90±0.28
MMP13/TIMP2 2.09±0.47 1.16±0.24 1.29±0.34 1.62±0.65 0.89±0.26 1.37±0.46
The MMP-2/TIMP-1, MMP-9/TIMP-1, and MMP-13/TIMP-1 ratios in the HDM-exposed mucosa were higher than the respective ratios in the control-exposed muco-
sa at 6 hr after NAC, but theratios did not differ significantly. However, the MMP2/TIMP1 and MMP13/TIMP1 ratios showed a tendency of difference.
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also called 72-kDa gelatinase (gelatinase A) and 92-kDa gelati-
nase (gelatinase B), respectively. MMP-2 degrades gelatin; type 
IV, V, VII, X, and XI collagens; fibronectin; elastin; and laminin.
10 
MMP-9 degrades gelatin; type IV, V, VII, and X collagens; elas-
tin; proteoglycan; entacin; fibronectin; and laminin.
9,10 Also 
called collagenase-3, MMP-13 degrades various substrates, in-
cluding fibrillar-type I, II, and III collagens; type IV, IX, X, and 
XIV collagens; gelatin; tenascin-C; fibronectin; and proteogly-
can core proteins.
10 Thus, all three MMPs can degrade type IV 
collagen, which is the major component of the basement mem-
brane zone.
The recruitment and migration of circulating inflammatory 
cells (e.g., eosinophils and basophils) to sites of inflammatory 
reactions in AR involve traversing capillary walls and the inter-
stitium,
5 which require the degradation of ECM proteins by se-
creted MMPs such as MMP-2 and MMP-9, which specifically 
degrade native type IV and V collagens and elastin.
6 Thickening 
of the basement membrane of the nasal mucosa and sloughed-
off epithelium with areas of epithelial metaplasia are also ob-
served in AR.
2,4 These pathological changes, which are caused 
by MMPs secreted by epithelial cells, fibroblasts, and inflam-
matory cells, are examples of tissue remodeling.
9,10 MMPs are 
also responsible for increased microvascular permeability, 
leading to edema and cell migration as well as ECM remodel-
ing at the site of inflammation.
8 This suggests that reducing 
MMP expression at sites of allergic inflammation may be an 
important strategy for treating symptoms of AR. In the present 
study, we analyzed the expression of MMP-2, MMP-9, MMP-
13, TIMP-1, and TIMP-2 in cells of the nasal mucosa of PAR pa-
tients at 30 minutes, 6 hours, and 12 hours after NAC with HDM 
allergens. We also analyzed their relationship to infiltrating mast 
cells and eosinophils in the allergic nasal mucosa.
AR is an inflammatory condition of the nasal mucosa caused 
by an allergen-IgE interaction in sensitized individuals. Histo-
Fig. 6. Correlation between MMP-13+ cells and eosinophils in the nasal muco-
sa of PAR patients. The number of eosinophils was strongly correlated with the 
number of MMP-13+ cells at 12 hr after NAC with HDM allergen disks (r=0.75, 
P<0.05, by Spearman’s rank correlation coefficient; n=10).
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logical observations have revealed structural abnormalities of 
the nasal mucosa, including thickening of the basement mem-
brane and structural fibrosis, which are associated with intense 
infiltration by several types of inflammatory cells such as eosin-
ophils and mast cells/basophils.
11,23,24 These cellular events in-
volve extensive alteration of the tissue ECM,
14 which is involved 
in tissue homeostasis as well as pathological conditions. Two 
groups of proteins, MMPs and TIMPs, are important factors for 
maintaining ECM homeostasis.
9,25,26 MMPs are produced by 
numerous cell types, including fibroblasts and macrophages, in 
response to inflammatory stimulation, and they mediate trans-
migration of eosinophils and macrophages through the base-
ment membrane to propagate inflammation.
25,27
In the present study, the expression of MMP-2, MMP-9, MMP-
13, TIMP-1, and TIMP-2 was significantly increased in the nasal 
mucosa of PAR patients at 30 minutes after NAC, suggesting that 
MMP-2, MMP-9, and MMP-13 may be crucial participants in 
the early-phase reaction, possibly by degrading the basement 
membrane to facilitate inflammatory cell migration into the al-
lergic nasal epithelial layer. There was a strong correlation be-
tween the numbers of MMP-9+ cells and mast cells at 30 min-
utes post-NAC. At 12 hours post-NAC, MMP-13 expression 
tended to be increased, and there was a strong correlation be-
tween the number of MMP-13+ cells and the number of eosin-
ophils. This suggests that MMP-9 may have an important role in 
the early-phase migration of mast cells into the epithelial com-
partment, while MMP-13 may participate in eosinophil recruit-
ment/migration during the late-phase reaction in allergic nasal 
mucosa.
High MMP-9 expression has been reported in the lower air-
way walls of asthmatics.
7,27 In our previous study, nasal polyps 
Fig. 7. The levels of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2, as deter-
mined by specific ELISA, in the nasal mucosa of PAR patients. MMP-2 and 
MMP-13 levels were higher than the MMP-9 level, and the TIMP-2 level was 
higher than the TIMP-1 level in allergic nasal mucosa. *P<0.05, **P<0.01, 
Wilcoxon signed-rank test; n=6.
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exhibited much higher MMP-9 expression and lower TIMP ex-
pression compared with the present levels in nasal mucosa.
22 
Although the MMP-9-to-TIMP ratio was high after NAC in the 
present study, it was still lower than that in nasal polyps (data 
not shown). The expression levels of MMP-9, MMP-2, and TIMP-
1 in nasal polyps of patients with comorbid AR were more 
prominent than those in the control group.
28 More recently, in-
creased expression of MMP-9 and TIMP-1 was detected in the 
nasal septal mucosa of an allergic rhinitis murine model.
29 Thus, 
MMP-9 in allergic nasal mucosa may contribute to the migra-
tion or recruitment of eosinophils, but may not be sufficient to 
induce structural changes such as those observed in nasal pol-
yps or asthma. At 6 hours post-NAC in the present study, al-
though the numbers of MMP-2+, MMP-9+, and MMP-13+ cells 
were not significantly higher in HDM-exposed nasal mucosa 
compared with control nasal mucosa, the ratios of MMP+ cells 
to TIMP-1+ cells were higher in HDM-exposed mucosa. This 
suggests that a relatively low TIMP-1 level may facilitate the ac-
tivities of MMP-2, MMP-9, and MMP-13 related to cell migration 
during the late-phase allergic reaction.
An imbalance between MMP-9 and TIMP-1 in induced spu-
tum is associated with airway inflammation in asthma and 
chronic obstructive pulmonary disease.
30 In the present study, 
we demonstrated for the first time that the levels of MMP-2, 
MMP-9 and MMP-13 are high relative to the levels of TIMP-1 
and TIMP-2 in ongoing chronic inflammation of PAR and that 
MMP+ cells are correlated with mast cells in the early phase 
and with eosinophils in the late phase of the inflammatory re-
action. The imbalance between MMPs and TIMPs may contrib-
ute to inflammatory cell migration in the nasal mucosa of AR 
patients. These findings suggest a possible active role of MMPs 
in the pathomechanism of AR.
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